AXON

Earnings season is rarely all one thing or the other. While  Palantir reported an “otherworldly” result and Arista, Unity, Cloudflare and JFrog results were not far behind, the earnings that were reported last evening left something to be desired-quite a bit when it came to AppLovin and some ambiguities when it came to Axon and Figma. At the end of…

To access this post, you must subscribe.

Read More

Everpure shares have recently spiked. They are up by almost 14% over the past week. I decided to trim the position in the high growth portfolio and sold 400 shares at $88.51. The sale raised $35,395. . This reduced the position to 2400 shares with a weight 6.91 % in the high growth portfolio. The portfolio…

To access this post, you must subscribe.

Read More

After yesterday’s spike in shares of most high-growth software companies, the market has cooled down quite a bit and is giving the high growth portfolio the opportunity to add to some positions where there have been positive developments and negative share price reaction. Much of yesterday’s spike was a function of what I think was…

To access this post, you must subscribe.

Read More

I made some changes in the High Growth portfolio this morning. I sold half of the Datadog position after its recent run. I think the shares are likely to consolidate after a 66% run in the past month. I decided to redeploy the funds to other positions that I believe have a grade potential for…

To access this post, you must subscribe.

Read More

We added to 3 positions in the high growth portfolio and added a new company as well. These positions essentially replaced the sale we made yesterday of Nebius which raised about $78k. The purchases were as follows: 1) 250 shares of Tempus AI @ $50.39-purchase cost of $12,605 and weight of 0.55%. The Tempus purchase is obviously…

To access this post, you must subscribe.

Read More

The stock market, after making several daily records, is under pressure today. Hi-growth software stocks have fallen and ServiceNow shares along with shares of IBM have seen significant drawdowns. I strongly felt that the sell-off in Service Now was not a reasonable interpretation of the quarter just reported and added to the position. And overall, I used the proceeds…

To access this post, you must subscribe.

Read More

Alphotographic/iStock via Getty Images What’s new at Axon: Operationally business has seen strong positive trends; the stock price has become compressed It has been 18 months since I last wrote about Axon (AXON) for SA. After rising to almost $900 a share before a poorly received earnings report, the shares have fallen by no less than 59% since…

To access this post, you must subscribe.

Read More

I made some changes in the high growth portfolio this morning. I decided to sell 500 more shares of Nebius shortly after the opening and I got a fill at $167.29. There is an old Wall St. saying about trees not growing to heaven. Nebius is up 95% so far this year. I have presented my model…

To access this post, you must subscribe.

Read More

Axon’s run: What should readers do now? It has been little more than a year since I first recommended Axon (AXON) shares. So far in 2024, the shares are up 68% and they have consistently been making new all-time highs. The quintessential pattern of a momentum growth stock. Much of the share price increase has come since the latest earnings…

To access this post, you must subscribe.

Read More